Latest News and Press Releases

HBC Immunology Inc. (70.6% owned by Hofseth BioCare ASA) reports today the successful completion of the first in vivo study within its prostate cancer development program. The study assessed whether...

Reference is made to the stock exchange announcement on 4 January 2024 regarding the conclusion of an extraordinary general meeting in Hofseth Biocare ASA ("HBC" or the "Company") whereby the general...

Hofseth Biocare ASA ("HBC" or the "Company") has today, on 4 January 2024, completed an extraordinary general meeting. All items proposed on the agenda were adopted, including the share capital...

Reference is made to the stock exchange notice announced by Hofseth Biocare ASA ("HBC" or the "Company") on 14 December regarding the notice for an extraordinary general meeting to be held at the...

Reference is made to the stock exchange notice announced by Hofseth Biocare ASA ("HBC" or the "Company") on 13 December regarding an investment of NOK 144 million from Hofseth International AS...

The board of directors (the “Board”) of Hofseth BioCare ASA ("HBC" or the "Company") has reached an agreement with Hofseth International AS (“Hofseth International”) whereby HBC will issue a new class...

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Reference is made to the mandatory notification of trade by Hofseth...

Hofseth International AS, a close associate of Board member Roger Hofseth, has today agreed to acquire 435,207 shares in Hofseth BioCare ASA (the "Company"). The shares are purchased at a price of NOK...

The third quarter of 2023 shows a significant growth of forty percent in sales compared to the same period last year and the increase in margins in Q2 continues. Sales revenues ended at NOK 49.9m vs...

The second quarter of 2023 shows a 100 % growth in sales compared to the same period last year and strong increase in margins. Sales revenues ended at NOK 52.9m vs NOK 25.8m last year. The underlying...